Controversial Alzheimer’s drug might value US $334B—practically half of DoD finances

https://ift.tt/eA8V8J
Enlarge / Pedestrians stroll previous Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Biogen Inc. shares soared after its controversial Alzheimer’s illness remedy was accredited by US regulators. Getty | Bloomberg Concern is mounting over the value of the controversial new Alzheimer’s drug Aduhelm. Advocates, lawmakers, and critics fear particularly about what …
Source: https://ift.tt/2UbIBu8